RITUXIMAB BETA

UNII:	WW3AY3N8RS
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	RITUXIMAB BETA
GSRS Full Record:	WW3AY3N8RS i

3062244-96-3
H-gamma1 heavy chain chimeric (1-451) [VH (Mus musculus IGHV1-47-27*01 (99.0%) -(IGHD) -IGHJ1*01 (87.5%) S128>A (121), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (218), V121>A (219) (122-219), hinge 1-15 (220-234), CH2 (235-344), CH3 D12 (360), L14 (362) (345-449), CHS (450-451)) (122-451)], (224-213')-disulfide with L-kappa light chain chimeric (1'-213') [V-KAPPA (Mus musculus IGKV4-72*01 (95.8%) -IGKJ1*01 (100%), CDR-IMGT [5.3.9] (27'-31'.49'-51'.88'-96')) (1'-106') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (152'), V101 (190')) (107'-213')]; dimer (230-230":233-233")-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa
Immunoglobulin G1, anti-(human CD20 antigen) (human-Mus musculus monoclonal GB241 γ1-chain), disulfide with human-Mus musculus monoclonal GB241 κ-chain, dimer (rituximab beta)
Rituximab Beta
Rituximab afucosylated glycoform
immunoglobulin G1-kappa, anti-[Homo sapiens MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], chimeric monoclonal antibody (rituximab beta)
rituximab beta [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

RITUXIMAB BETA

Synonyms and Mappings

Resources